Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price increase of 57.80%. However, over the past six months, we’ve seen a weaker performance of 66.09%. The price of MLYS fallen by 16.04% over the last 30 days. And in the last five days, it has surged by 14.16%.
The stock price for Mineralys Therapeutics Inc (MLYS) currently stands at $15.48. The stock experienced a substantial increase in the last session, hitting $48.0 after starting at $15.48. The stock’s lowest price was $15.0 before closing at $14.47.
In terms of market performance, Mineralys Therapeutics Inc had a fairly even. The highest value for the stock in the past year was $18.38 on 03/19/25, and the lowest value was recorded at $8.24 on 02/25/25.
52-week price history of MLYS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Mineralys Therapeutics Inc’s current trading price is -15.78% away from its 52-week high, while its distance from the 52-week low is 87.84%. The stock’s price range during this period has varied between$8.24 and $18.38. The Mineralys Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.1 million for the day, a figure considerably higher than their average daily volume of 0.81 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Mineralys Therapeutics Inc (MLYS) has experienced a quarterly decline of -3.85% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.03B and boasts a workforce of 51 employees.
Mineralys Therapeutics Inc: Analysts’ Ratings Unveiled
As of right now, 7 analysts are rating Mineralys Therapeutics Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 14.34, with a change in price of +0.48. Similarly, Mineralys Therapeutics Inc recorded 881,984 in trading volume during the last 100 days, posting a change of +3.20%.
MLYS Stock Stochastic Average
Mineralys Therapeutics Inc’s raw stochastic average for the past 50 days is presently 70.87%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 97.64%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 84.68% and 79.37%, respectively.
